Pulse Journal Club Trending Explore Questions Researchers

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Privacy Policy

Home Explore Journal Club Trending

⌘+K

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia | Synapse

February 1, 2020Open Access

Long-Term Evolocumab in Patients With Familial Hypercholesterolemia

Key Points

Key points are not available for this paper at this time.

Abstract

Evolocumab was well tolerated and effectively reduced plasma LDL-C levels in patients with HoFH and severe HeFH over a median of 4.1 years.

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper

Mark Helpful

Bookmark

Relay

View Full Paper

Cite This Study

Santos et al. (Sat,) studied this question.

synapsesocial.com/papers/6973ad754850f876c58a3ed8 https://doi.org/https://doi.org/10.1016/j.jacc.2019.12.020

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Mechanisms of Disease: genetic causes of familial hypercholesterolemia2007 · 611 citations
2Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia2002 · 483 citations
3Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol2017 · 123 citations
4Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial2014 · 726 citations
5Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study2012 · 739 citations